Modulation of behavior by the histaminergic system: Lessons from H1R-and H2R-deficient mice

Neuroscience and Biobehavioral Reviews

Volumn 42, Issue , 2014, Pages 252-266

  Schneider, Erich H ^a   Neumann, Detlef ^a   Seifert, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Behavior; Brain; Circadian rhythm; Food intake; Histamine receptor; Knockout mouse; Learning; Memory; Pain; Respiration; Seizures; Sleep

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; MELANOCORTIN 4 RECEPTOR; UNCOUPLING PROTEIN 1;

AEROBIC METABOLISM; ANIMAL BEHAVIOR; AROUSAL; BREATHING; CIRCADIAN RHYTHM; EMOTIONALITY; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FOOD INTAKE; HISTAMINE RELEASE; HUMAN; IMMUNOMODULATION; LEARNING; LOCOMOTION; MEMORY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEIZURE; SLEEP WAKING CYCLE; ANIMAL; BEHAVIOR; BRAIN; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; BEHAVIOR; BRAIN; HUMANS; MICE, KNOCKOUT; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H2;

EID: 84897398159     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.03.009     Document Type: Review

References (138)

1. Airaksinen M.S., Paetau A., Paljärvi L., Reinikainen K., Riekkinen P., Suomalainen R., Panula P. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 1991, 44:465-481.
2. Anichtchik O.V., Rinne J.O., Kalimo H., Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 2000, 163:20-30.
3. 3-receptors control histamine release in human brain. J. Neurochem. 1988, 51:105-108.
4. Arrang J.M., Garbarg M., Quach T.T., Dam Trung Tuong M., Yeramian E., Schwartz J.C. Actions of betahistine at histamine receptors in the brain. Eur. J. Pharmacol. 1985, 111:73-84.
5. Barnett A., Malick J.B., Taber R.I. Effects of antihistamines on isolation-induced fighting in mice. Psychopharmacologia 1971, 19:359-365.
6. Bassetti C.L., Baumann C.R., Dauvilliers Y., Croyal M., Robert P., Schwartz J.C. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J. Sleep Res. 2010, 19:620-623.
7. Bekkers J.M. Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 1993, 261:104-106.
8. Bongers G., de Esch I., Leurs R. Molecular pharmacology of the four histamine receptors. Adv. Exp. Med. Biol. 2010, 709:11-19.
9. Burban A., Faucard R., Armand V., Bayard C., Vorobjev V., Arrang J.M. Histamine potentiates N-methyl-d-aspartate receptors by interacting with an allosteric site distinct from the polyamine binding site. J. Pharmacol. Exp. Ther. 2010, 332:912-921.
10. Cerminara C., El-Malhany N., Roberto D., Lo Castro A., Curatolo P. Seizures induced by desloratadine, a second-generation antihistamine: clinical observations. Neuropediatrics 2013, 44:222-224.
11. Chaves K.M., Serrano-Blanco A., Ribeiro S.B., Soares L.A., Guerra G.C., do Socorro Costa Feitosa Alves M., de Araujo Junior R.F., de Paula Soares Rachetti V., Filgueira Junior A., de Araujo A.A. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr. Q. 2013, 84:125-135.
12. v mice. Brain Res. 2003, 968:162-166.
13. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science 1999, 284:1670-1672.
14. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl.) 1997, 132:107-124.
15. Croyal M., Dauvilliers Y., Labeeuw O., Capet M., Schwartz J.C., Robert P. Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization. Anal. Biochem. 2011, 409:28-36.
16. 2 receptors. Neurosci. Res. 2007, 57:306-313.
17. 1 receptor gene knockout mice. Psychopharmacology (Berl.) 2005, 183:285-293.
18. Dauvilliers Y., Delallée N., Jaussent I., Scholz S., Bayard S., Croyal M., Schwartz J.C., Robert P. Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep 2012, 35:1359-1366.
19. Deng C., Lian J., Pai N., Huang X.F. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J. Psychopharmacol. 2012, 26:1271-1279.
20. 1 receptor knockout mice coincide with changes in acetylcholine esterase activity in the hippocampus and dopamine turnover in the cerebellum. Neuroscience 2008, 157:532-541.
21. 1 receptor blockade. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358:423-429.
22. Dutschmann M., Bischoff A.M., Busselberg D., Richter D.W. Histaminergic modulation of the intact respiratory network of adult mice. Pflügers Arch. 2003, 445:570-576.
23. Easton A., Norton J., Goodwillie A., Pfaff D.W. Sex differences in mouse behavior following pyrilamine treatment: role of histamine 1 receptors in arousal. Pharmacol. Biochem. Behav. 2004, 79:563-572.
24. García-Martín E., Ayuso P., Luengo A., Martínez C., Agúndez J.A. Genetic variability of histamine receptors in patients with Parkinson's disease. BMC Med. Genet. 2008, 9:15. 10.1186/1471-2350-9-15.
25. Gotoh K., Fukagawa K., Fukagawa T., Noguchi H., Kakuma T., Sakata T., Yoshimatsu H. Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine interact in the leptin-signaling pathway to regulate feeding behavior. FASEB J. 2005, 19:1131-1133.
26. Gotoh K., Fukagawa K., Fukagawa T., Noguchi H., Kakuma T., Sakata T., Yoshimatsu H. Hypothalamic neuronal histamine mediates the thyrotropin-releasing hormone-induced suppression of food intake. J. Neurochem. 2007, 103:1102-1110.
27. Gotoh K., Masaki T., Chiba S., Ando H., Shimasaki T., Mitsutomi K., Fujiwara K., Katsuragi I., Kakuma T., Sakata T., Yoshimatsu H. Nesfatin-1, corticotropin-releasing hormone, thyrotropin-releasing hormone, and neuronal histamine interact in the hypothalamus to regulate feeding behavior. J. Neurochem. 2013, 124:90-99.
28. Gotoh K., Masaki T., Chiba S., Higuchi K., Kakuma T., Shimizu H., Mori M., Sakata T., Yoshimatsu H. Hypothalamic neuronal histamine signaling in the estrogen deficiency-induced obesity. J. Neurochem. 2009, 110:1796-1805.
29. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241.
30. Haruyama W., Fuchigami T., Noguchi Y., Endo A., Hashimoto K., Inamo Y., Fujita Y., Takahashi S., Mugishima H. The relationship between drug treatment and the clinical characteristics of febrile seizures. World J. Pediatr. 2008, 4:202-205.
31. He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013, 27:423-434.
32. Henann N.E., Carpenter D.U., Janda S.M. Famotidine-associated mental confusion in elderly patients. Drug Intell. Clin. Pharm. 1988, 22:976-978.
33. 1 receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 2000, 99:721-729.
34. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.C., Shankley N.P., Young J.M., Schunack W., Levi R., Haas H.L. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 1997, 49:253-278.
35. 1 receptor-deficient mice. Epilepsia 2004, 45:309-313.
36. Hondo M., Nagai K., Ohno K., Kisanuki Y., Willie J.T., Watanabe T., Yanagisawa M., Sakurai T. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol. (Oxf.) 2010, 198:287-294.
37. 1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4687-4692.
38. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9965-9970.
39. 1 receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13316-13320.
40. Ishiguro T., Iwase M., Kanamaru M., Izumizaki M., Ohshima Y., Homma I. Contribution of histamine type-1 receptor to metabolic and behavioral control of ventilation. J. Physiol. Sci. 2006, 56:287-295.
41. 1 receptor-knockout mice. Respir. Physiol. Neurobiol. 2006, 154:331-341.
42. Ishizuka T., Nomura S., Hosoda H., Kangawa K., Watanabe T., Yamatodani A. A role of the histaminergic system for the control of feeding by orexigenic peptides. Physiol. Behav. 2006, 89:295-300.
43. 2 receptor gene variants: lack of association with schizophrenia. Mol. Psychiatry 2000, 5:159-164.
44. Iwabuchi K., Kubota Y., Ito C., Watanabe T., Watanabe T., Yanai K. Methamphetamine and brain histamine: a study using histamine-related gene knockout mice. Ann. N.Y. Acad. Sci. 2004, 1025:129-134.
45. Iwase M., Homma I., Shioda S., Nakai Y. Histamine immunoreactive neurons in the brain stem of the rabbit. Brain Res. Bull. 1993, 32:267-272.
46. Iwase M., Izumizaki M., Miyamoto K., Ishiguro T., Kanamaru M., Homma I. Lack of histamine type-1 receptors impairs the thermal response of respiration during hypoxia in mice (Mus musculus). Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 2007, 146:242-251.
47. 1 receptors in mice. Adv. Exp. Med. Biol. 2010, 669:235-238.
48. 1 receptor-deficient mice. Neurosci. Lett. 2000, 284:139-142.
49. Jørgensen E.A., Knigge U., Watanabe T., Warberg J., Kjaer A. Histaminergic neurons are involved in the orexigenic effect of orexin-A. Neuroendocrinology 2005, 82:70-77.
50. John J., Thannickal T.C., McGregor R., Ramanathan L., Ohtsu H., Nishino S., Sakai N., Yamanaka A., Stone C., Cornford M., Siegel J.M. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 2013, (Epub ahead of print). 10.1002/ana.23968.
51. Jutel M., Akdis M., Akdis C.A. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy 2009, 39:1786-1800.
52. Kagevi I., Thorhallsson E., Wählby L. CSF concentrations of famotidine. Br. J. Clin. Pharmacol. 1987, 24:849-850.
53. 1-antihistamines: an update. Antiinflamm. Antiallergy Agents Med. Chem. 2012, 11:230-237.
54. Kanbayashi T., Kodama T., Kondo H., Satoh S., Inoue Y., Chiba S., Shimizu T., Nishino S. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009, 32:181-187.
55. 1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 2004, 20:803-810.
56. Köhler C.A., da Silva W.C., Benetti F., Bonini J.S. Histaminergic mechanisms for modulation of memory systems. Neural Plast. 2011, 2011:328602.
57. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
58. Kukko-Lukjanov T.K., Gronman M., Lintunen M., Lauren H.B., Michelsen K.A., Panula P., Holopainen I.E. Histamine 1 receptor knock out mice show age-dependent susceptibility to status epilepticus and consequent neuronal damage. Epilepsy Res. 2012, 100:80-92.
59. Kukko-Lukjanov T.K., Lintunen M., Jalava N., Lauren H.B., Lopez-Picon F.R., Michelsen K.A., Panula P., Holopainen I.E. Involvement of histamine 1 receptor in seizure susceptibility and neuroprotection in immature mice. Epilepsy Res. 2010, 90:8-15.
60. 1 receptors mediate l-histidine-induced anxiety in elevated plus-maze test in mice. Behav. Pharmacol. 2007, 18:213-217.
61. Lamberti C., Bartolini A., Ghelardini C., Malmberg-Aiello P. Investigation into the role of histamine receptors in rodent antinociception. Pharmacol. Biochem. Behav. 1996, 53:567-574.
62. 3 agonists on food and water intake and urine flow in Wistar rats. Brain Res. 1998, 793:279-288.
63. Leza J.C., Lizasoain I., Lorenzo P. Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity. Gen. Pharmacol. 1991, 22:293-296.
64. Lieberman P. Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc. 2009, 30:482-486.
65. Lin L., Wisor J., Shiba T., Taheri S., Yanai K., Wurts S., Lin X., Vitaterna M., Takahashi J., Lovenberg T.W., Koehl M., Uhl G., Nishino S., Mignot E. Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background. Peptides 2002, 23:2203-2211.
66. Madhusoodanan S., Brenner R., Gupta S., Reddy H., Bogunovic O. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004, 9:862-867.
67. 1 receptor activation in rodents. Life Sci. 1998, 63:463-476.
68. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., Elmquist J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001, 435:6-25.
69. Martinez M.C. Famotidine in the management of schizophrenia. Ann. Pharmacother. 1999, 33:742-747.
70. 1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004, 53:2250-2260.
71. y/a obese mice. Endocrinology 2003, 144:2741-2748.
72. Masaki T., Yoshimatsu H. Molecular mechanisms of neuronal histamine and its receptors in obesity. Curr. Mol. Pharmacol. 2009, 2:249-252.
73. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001, 50:376-384.
74. 1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001, 50:385-391.
75. Masukawa Y., Suzuki T., Misawa M. Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines. Psychopharmacology (Berl.) 1993, 111:139-143.
76. Meskanen K., Ekelund H., Laitinen J., Neuvonen P.J., Haukka J., Panula P., Ekelund J. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J. Clin. Psychopharmacol. 2013, 33:472-478.
77. Miyamoto K., Iwase M., Kimura H., Homma I. Central histamine contributes to the inspiratory off-switch mechanism via H1 receptors in mice. Respir. Physiol. Neurobiol. 2004, 144:25-33.
78. 1 receptor gene knockout mice. Neuropharmacology 2002, 42:1079-1088.
79. 1 receptor in pain perception: a study of the receptor gene knockout mice. Eur. J. Pharmacol. 2000, 391:81-89.
80. 2 receptor gene knockout mice. Neuropharmacology 2006, 51:612-622.
81. 2 receptor gene knockout mice. Pain 2005, 118:254-262.
82. Morimoto T., Yamamoto Y., Mobarakeh J.I., Yanai K., Watanabe T., Watanabe T., Yamatodani A. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav. 1999, 67:679-683.
83. Morimoto T., Yamamoto Y., Yamatodani A. Brain histamine and feeding behavior. Behav. Brain Res. 2001, 124:145-150.
84. Morisset S., Sahm U.G., Traiffort E., Tardivel-Lacombe J., Arrang J.M., Schwartz J.C. Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J. Pharmacol. Exp. Ther. 1999, 288:590-596.
85. Mosienko V., Bert B., Beis D., Matthes S., Fink H., Bader M., Alenina N. Exaggerated aggression and decreased anxiety in mice deficient in brain serotonin. Transl. Psychiatry 2012, 2:e122.
86. 2 receptor in the regulation of feeding behavior through the histaminergic system. Neuropharmacology 2011, 61:228-233.
87. Neumann D., Schneider E.H., Seifert R. Analysis of histamine receptor knock-out mice in models of inflammation. J. Pharmacol. Exp. Ther. 2014, 348:2-11.
88. Nishino S., Sakurai E., Nevsimalova S., Yoshida Y., Watanabe T., Yanai K., Mignot E. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009, 32:174-180.
89. 1 receptor blocking. Physiol. Behav. 1992, 51:1123-1127.
90. 2 antagonists on motor activity. Pharmacol. Biochem. Behav. 1987, 26:683-686.
91. 2 receptor knock-out mice. Brain Res. Bull. 2009, 78:189-194.
92. 1 receptor in mice. Peptides 2004, 25:2135-2138.
93. 1 receptor in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R1350-R1356.
94. 1 receptors in mice. J. Physiol. Sci. 2011, 61:73-82.
95. 1 receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward. Eur. J. Pharmacol. 2012, 683:161-165.
96. 2 receptor gene. Mol. Psychiatry 1996, 1:466-469.
97. Ota M., Mori K., Nakashima A., Kaneko Y.S., Fujiwara K., Itoh M., Nagasaka A., Ota A. Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin. Exp. Pharmacol. Physiol. 2002, 29:980-989.
98. Panula P., Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 2013, 14:472-487.
99. Poyurovsky M., Fuchs C., Pashinian A., Levi A., Weizman R., Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl.) 2013, 226:615-622.
100. Pramyothin P., Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:460-466.
101. Raffa R.B. Antihistamines as analgesics. J. Clin. Pharm. Ther. 2001, 26:81-85.
102. Randeva H.S., Karteris E., Grammatopoulos D., Hillhouse E.W. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J. Clin. Endocrinol. Metab. 2001, 86:4808-4813.
103. Redmond A.M., Pentapaty N., Weibel J., Nolan S.F., Hudson J.Q., Self T. Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes. Am. J. Med. Sci. 2005, 330:8-10.
104. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol. Ther. 2010, 125:169-179.
105. Rinne J.O., Anichtchik O.V., Eriksson K.S., Kaslin J., Tuomisto L., Kalimo H., Röyttä M., Panula P. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 2002, 81:954-960.
106. Rosse R.B., Kendrick K., Fay-McCarthy M., Prell G.D., Rosenberg P., Tsui L.C., Wyatt R.J., Deutsch S.I. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin. Neuropharmacol. 1996, 19:341-348.
107. Sakurada S., Watanabe H., Mizoguchi H., Yonezawa A., Orito T., Katsuyama S., Kuramasu A., Sakurada C., Yanai K., Sakurada T. Involvement of the histaminergic system in the nociceptin-induced pain-related behaviors in the mouse spinal cord. Pain 2004, 112:171-182.
108. 3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 2011, 163:713-721.
109. Seifert R., Strasser A., Schneider E.H., Neumann D., Dove S., Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol. Sci. 2013, 34:33-58.
110. 2 receptors. Conference of the Society for Neuroscience 2001, Abstract 745.15.
111. Shin J.M., Vagin O., Munson K., Kidd M., Modlin I.M., Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell. Mol. Life Sci. 2008, 65:264-281.
112. 1 receptor-mediated inhibition of potassium-evoked release of 5-hydroxytryptamine from mouse forebrains. Behav. Brain Res. 2001, 124:113-120.
113. Strasser A., Wittmann H.J., Buschauer A., Schneider E.H., Seifert R. Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs. Trends Pharmacol. Sci. 2013, 34:13-32.
114. Takahashi K., Lin J.S., Sakai K. Neuronal activity of histaminergic tuberomammillary neurons during wake-sleep states in the mouse. J. Neurosci. 2006, 40:10292-10298.
115. Takino N., Sakurai E., Kuramasu A., Okamura N., Yanai K. Roles of the histaminergic neurotransmission on methamphetamine-induced locomotor sensitization and reward: a study of receptors gene knockout mice. Int. Rev. Neurobiol. 2009, 85:109-116.
116. Thakkar M.M. Histamine in the regulation of wakefulness. Sleep Med. Rev. 2011, 15:65-74.
117. Tsuda K., Yoshimatsu H., Niijima A., Chiba S., Okeda T., Sakata T. Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp. Biol. Med. (Maywood) 2002, 227:208-213.
118. Valko P.O., Gavrilov Y.V., Yamamoto M., Reddy H., Haybaeck J., Mignot E., Baumann C.R., Scammell T.E. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 2013, (Epub ahead of print). 10.1002/ana.24019.
119. Vorobjev V.S., Sharonova I.N., Walsh I.B., Haas H.L. Histamine potentiates N-methyl-d-aspartate responses in acutely isolated hippocampal neurons. Neuron 1993, 11:837-844.
120. Wahlsten D., Metten P., Phillips T.J., Boehm S.L., Burkhart-Kasch S., Dorow J., Doerksen S., Downing C., Fogarty J., Rodd-Henricks K., Hen R., McKinnon C.S., Merrill C.M., Nolte C., Schalomon M., Schlumbohm J.P., Sibert J.R., Wenger C.D., Dudek B.C., Crabbe J.C. Different data from different labs: lessons from studies of gene-environment interaction. J. Neurobiol. 2003, 54:283-311.
121. Walf A.A., Frye C.A. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006, 31:1097-1111.
122. Walter M., Stark H. Histamine receptor subtypes: a century of rational drug design. Front. Biosci. (Schol. Ed.) 2012, 4:461-488.
123. Watanabe C., Orito T., Watanabe H., Mizoguchi H., Yonezawa A., Yanai K., Mobarakeh J.I., Onodera K., Sakurada T., Sakurada S. Intrathecal high-dose histamine induces spinally-mediated nociceptive behavioral responses through a polyamine site of NMDA receptors. Eur. J. Pharmacol. 2008, 581:54-63.
124. Williams K. Subunit-specific potentiation of recombinant N-methyl-d-aspartate receptors by histamine. Mol. Pharmacol. 1994, 46:531-541.
125. Xiang Y.T., Wang C.Y., Ungvari G.S., Kreyenbuhl J.A., Chiu H.F., Lai K.Y., Lee E.H., Bo Q.J., Dixon L.B. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry 2011, 44:135-141.
126. 2 receptors in gene knockout mice. Conference of the Society for Neuroscience 2006, Abstract 507.7.
127. 1 receptors on cognition. Inflamm. Res. 2008, 57(Suppl. 1):S39-S40.
128. 1 receptors. Neuroscience 1998, 87:479-487.
129. 1 receptors in mice: behavioral and neurochemical characterization. Life Sci. 1998, 62:1607-1610.
130. 1 receptor in human brains revealed by PET. Neuroreport 1992, 3:433-436.
131. Yasuda S.U., Yasuda R.P. Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy 1999, 19:447-451.
132. Yasuda T., Masaki T., Sakata T., Yoshimatsu H. Hypothalamic neuronal histamine regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose tissue in rats. Neuroscience 2004, 125:535-540.
133. 1-antagonists on electrically-induced seizure in developing mice. Psychopharmacology (Berl.) 1993, 112:199-203.
134. Yoshimatsu H. Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm. Nutrition 2008, 24:827-831.
135. 1 receptor binding in patients with anorexia nervosa. Biol. Psychiatry 2009, 65:329-335.
136. 1 receptor and recollection-based discrimination in a temporal order memory task in the mouse. Pharmacol. Biochem. Behav. 2013, 111C:58-63.
137. 1 receptor knockout mice exhibit impaired spatial memory in the eight-arm radial maze. Br. J. Pharmacol. 2009, 157:86-91.
138. 1-receptor mediates the motivational effects of novelty. Eur. J. Neurosci. 2008, 27:1461-2147.